Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(22)00791-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
History and Perspectives of Hyperradical, Laterally Extended Parametrectomy (LEP).
Ann Surg Oncol
October 2024
Semmelweis University, Budapest, Hungary.
Cervical cancer has been and still is a major global health problem and a major treatment challenge for which surgical interventions have played a key role throughout the past century. In early stages (I/A2-II/B), where high-risk factors are not present, the efficacy of surgical and radiotherapy treatment has been considered equivalent with different (treatment modality specific) complications and quality of life consequences. Negative prognostic factors in early stages of the disease (pelvic lymph-node positivity) and in more advanced stages (parametrial and/or surgical margins' tumor involvement) forecast the deterioration of outlooks for good life expectancy.
View Article and Find Full Text PDFConcurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.
Cancer Commun (Lond)
October 2024
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China.
Article Synopsis
- A phase III clinical trial was conducted to evaluate the effects of different radiation doses (high vs. standard) and irradiation fields (involved field vs. elective nodal) on survival outcomes for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
- Results indicated that there were no significant differences in overall survival (OS) or progression-free survival (PFS) between the different irradiation fields, but the high-dose treatment suggested an improvement in PFS compared to the standard dose.
- The best prognostic outcomes were observed in the high-dose with involved field group (HD+IFI), while the standard dose with involved field group (SD+IFI) had the worst outcomes, and no substantial differences in severe adverse events were
Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
Int J Surg
June 2024
Department of Radiation Oncology, The Fourth Affiliated Hospital of China Medical University, Liaoning, China.
Background: The aim was to explore the optimal neoadjuvant therapy strategy for resectable, borderline resectable, and locally advanced pancreatic cancer, in order to provide a theoretical basis for the development of new neoadjuvant treatment protocols for clinical use.
Patients And Methods: The authors reviewed literature titles and abstracts comparing three treatment strategies (neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy, and upfront surgery) in PubMed, Embase, The Cochrane Library, Web of Science from 2009 to 2023 to estimate relative odds ratios for resection rate and hazard ratios (HRs) for overall survival (OS) in all include trials.
Results: A total of nine studies involving 889 patients were included in the analysis.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet
April 2024
University of Virginia School of Medicine, Charlottesville, VA, USA.
Article Synopsis
- Pembrolizumab, an immunotherapy drug, is being tested to see if it improves the effectiveness of chemoradiotherapy in patients with locally advanced cervical cancer, based on prior success in similar cases.
- This phase 3 trial involved multiple international centers and used a double-blind, placebo-controlled design to randomly assign participants to receive either pembrolizumab or a placebo alongside their treatment.
- The primary goals of the study were to measure progression-free survival and overall survival, assessing treatment safety in those who received at least one dose of the study medication.
Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Cancer Res Treat
October 2024
Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Purpose: This study aimed to investigate the efficacy and safety of using metronomic S-1 adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials And Methods: We retrospectively collected data on patients diagnosed with LANPC between January 2016 and December 2021. All patients were treated with induction chemotherapy and concurrent chemoradiotherapy with or without metronomic chemotherapy (MC).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!